Showing results 1 to 3 of 3
Combination Therapy of the Active KRAS-Targeting Antibody inRas37 and a PI3K Inhibitor in Pancreatic Canceroa mark- Lee, Ji Eun;
- Woo, Min Gyu;
- Jung, Kyung Hee;
- Kang, Yeo Wool;
- Shin, Seung Min;
- Son, Mi Kwon;
- Fang, Zhenghuan;
- Yan, Hong Hua;
- Park, Jung Hee;
- Yoon, Young Chan;
et al
- 2022-05-01
- Biomolecules and Therapeutics, Vol.30 No.3, pp.274-283
- Korean Society of Applied Pharmacology
Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape- Lee, Ji Eun;
- Kang, Yeo Wool;
- Jung, Kyung Hee;
- Son, Mi Kwon;
- Shin, Seung Min;
- Kim, Ji Sun;
- Kim, Soo Jung;
- Fang, Zhenghuan;
- Yan, Hong Hua;
- Park, Jung Hee;
et al
- 2021-06-01
- Cancer Letters, Vol.507, pp.97-111
- Elsevier Ireland Ltd
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer- Kang, Yeo Wool;
- Lee, Ji Eun;
- Jung, Kyung Hee;
- Son, Mi Kwon;
- Shin, Seung Min;
- Kim, Soo Jung;
- Fang, Zhenghuan;
- Yan, Hong Hua;
- Park, Jung Hee;
- Han, Boreum;
et al
- 2018-12-01
- Cancer Letters, Vol.438, pp.174-186
- Elsevier Ireland Ltd
1
